These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 18022724)

  • 1. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH).
    Henriksen JH; Ring-Larsen H
    J Hepatol; 2008 Jan; 48(1):174-6. PubMed ID: 18022724
    [No Abstract]   [Full Text] [Related]  

  • 2. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
    Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
    Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commonly used animal models of non-alcoholic steatohepatitis.
    Fan JG; Qiao L
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis.
    Musso G; Gambino R; De Michieli F; Biroli G; Fagà E; Pagano G; Cassader M
    Ann Med; 2008; 40(5):383-94. PubMed ID: 18484349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of curcumin in non-alcoholic steatohepatitis.
    Shapiro H; Bruck R
    Nutr Res Rev; 2005 Dec; 18(2):212-21. PubMed ID: 19079906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model.
    Serviddio G; Bellanti F; Tamborra R; Rollo T; Romano AD; Giudetti AM; Capitanio N; Petrella A; Vendemiale G; Altomare E
    Eur J Clin Invest; 2008 Apr; 38(4):245-52. PubMed ID: 18339004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and therapy in NASH].
    Tokushige K
    Rinsho Byori; 2009 Sep; 57(9):848-53. PubMed ID: 19860210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
    Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
    Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
    Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
    Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis.
    Maeda T; Hashimoto K; Kihara Y; Ikegami T; Ishida T; Aimitsu S; Fujiwara M
    Hepatogastroenterology; 2008; 55(85):1404-6. PubMed ID: 18795699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis.
    Piro S; Spadaro L; Russello M; Spampinato D; Oliveri CE; Vasquez E; Benigno R; Brancato F; Purrello F; Rabuazzo AM
    Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):545-52. PubMed ID: 18063353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease: is bariatric surgery the answer?
    Pillai AA; Rinella ME
    Clin Liver Dis; 2009 Nov; 13(4):689-710. PubMed ID: 19818313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats.
    Zhou GD; Li MR; Zhang J; Pan D; Zhao SX; Yang JF; Yu J; Zhao JM
    Scand J Gastroenterol; 2008; 43(11):1371-7. PubMed ID: 18654934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Malik SM; Gupte PA; de Vera ME; Ahmad J
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):800-6. PubMed ID: 19281869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial involvement in non-alcoholic steatohepatitis.
    Serviddio G; Sastre J; Bellanti F; Viña J; Vendemiale G; Altomare E
    Mol Aspects Med; 2008; 29(1-2):22-35. PubMed ID: 18061659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice.
    Sasaki Y; Suzuki W; Shimada T; Iizuka S; Nakamura S; Nagata M; Fujimoto M; Tsuneyama K; Hokao R; Miyamoto K; Aburada M
    Life Sci; 2009 Sep; 85(13-14):490-8. PubMed ID: 19683013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.